Clinical Topics   /   Oncology

VA Researchers Show How Imatinib Improves Prognosis for Hard-to-Treat Cancer

By U.S. Medicine

By Annette M. Boyle

PORTLAND, OR — Not long ago, less than a third of chronic myeloid leukemia (CML) patients survived five years and gastrointestinal stromal tumor (GIST) patients had an even shorter life expectancy, according to the National Cancer Institute. Now significant numbers of patients with these cancers live for another 10 years after diagnosis.

What changed? Several recent studies, including some involving VA research, highlight the improved survival rates in multiple cancers since the development of imatinib kicked off the race to develop personalized, non-toxic therapies. Imatinib, a selective tyrosine kinase inhibitor that is administered orally, dramatically improved survival rates for both gastrointestinal stromal tumor (GIST) and (CML).

Before imatinib, “patients with advanced GISTs faced a life expectancy of 18 months,” said Michael Heinrich, MD, a researcher with Portland Veterans Affairs Health Care System and professor of medicine at the Oregon Health & Science University School of Medicine. “Now we’ve learned that some might live a decade or longer.”

GISTs are soft-tissue sarcomas that can occur anywhere in the gastrointestinal tract. About 6,000 new cases are diagnosed annually nationwide.

The long-term study appeared in the February issue of JAMA Oncology. Researchers followed 695 adults with advanced, inoperable gastrointestinal stromal tumors who were enrolled in a phase III study that started in 2000. A previous report on the study, published in 2008, confirmed imatinib’s effectiveness and recommended treatment with 400 mg daily dose. The initial study had randomized patients to receive either 400 mg per day or 800 mg daily, which was continued until progression or unacceptable toxic effects occurred.1

Of the initial participants, 189 survived for at least eight years and researchers estimated 10-year survival rates of 23% and progression-free survival rates of 7%. About equal numbers of the long-term survivors received 400 mg per day (95) or 800 mg per day (94) of imatinib.

Click to Enlarge


Related Articles

Shulkin Ousted, White House Physician Nominated for VA Secretary

WASHINGTON — After several weeks of speculation regarding his future in the Trump Administration, VA Secretary David Shulkin, MD’s tenure came to an abrupt end on March 28.

Congress Seeks More Oversight of VA EHR Program

WASHINGTON — Legislation under consideration by Congress would increase oversight of VA’s adoption and implementation of its forthcoming electronic health record (EHR) system. The VA announced last year that it would adopt the same Cerner... View Article


U.S. Medicine Recommends


More From department of veterans affairs

Department of Veterans Affairs (VA)

Shulkin Ousted, White House Physician Nominated for VA Secretary

WASHINGTON — After several weeks of speculation regarding his future in the Trump Administration, VA Secretary David Shulkin, MD’s tenure came to an abrupt end on March 28.

Department of Veterans Affairs (VA)

Congress Seeks More Oversight of VA EHR Program

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

Department of Veterans Affairs (VA)

Congress, VSOs Have Wait-and- See Position on Jackson Nomination

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

Department of Veterans Affairs (VA)

VA Vows to Meet Deadline for Revamp of Veteran Claims Appeal Process

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

Department of Veterans Affairs (VA)

Vets With Respiratory Disease More Responsive to ‘Quit’ Programs

BRONX, NY — For patients with chronic kidney disease (CKD), living more than 30 miles from their nephrologist is associated with many unfavorable outcomes. They have lower rates of clinic visit adherence, more limited access... View Article

Facebook Comment